Colchicine as a possible therapeutic option in COVID-19 infection.
作者信息
Parra-Medina Rafael, Sarmiento-Monroy Juan Camilo, Rojas-Villarraga Adriana, Garavito Edgar, Montealegre-Gómez Giovanni, Gómez-López Arley
机构信息
Department of Pathology, Fundación Universitaria de Ciencias de la Salud, Institución, Cra. 19 N 8ª-32, Bogotá, Colombia.
Research Institute, Fundación Universitaria de Ciencias de la Salud, Institución, Cra. 19 N 8ª-32, Bogotá, Colombia.
出版信息
Clin Rheumatol. 2020 Aug;39(8):2485-2486. doi: 10.1007/s10067-020-05247-5. Epub 2020 Jun 18.
Abstract
摘要
相似文献
1
Colchicine as a possible therapeutic option in COVID-19 infection.秋水仙碱作为治疗新冠病毒感染的一种可能选择。
Clin Rheumatol. 2020 Aug;39(8):2485-2486. doi: 10.1007/s10067-020-05247-5. Epub 2020 Jun 18.
2
Colchicine and COVID-19.秋水仙碱与新型冠状病毒肺炎
J Clin Pharmacol. 2020 Aug;60(8):978. doi: 10.1002/jcph.1684. Epub 2020 Jun 24.
3
Comment on "Colchicine may not be effective in COVID-19 infection; it may even be harmful?".关于“秋水仙碱可能对新冠病毒感染无效；甚至可能有害？”的评论
Clin Rheumatol. 2020 Aug;39(8):2487-2488. doi: 10.1007/s10067-020-05233-x. Epub 2020 Jun 20.
4
The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al.秋水仙碱在COVID-19中应用的理论依据：对Cumhur Cure M等人信件的评论
Clin Rheumatol. 2020 Aug;39(8):2489-2490. doi: 10.1007/s10067-020-05232-y. Epub 2020 Jun 20.
5
Why not to use colchicine in COVID-19? An oldanti-inflammatory drug for a novel auto-inflammatory disease.为何不在新冠肺炎治疗中使用秋水仙碱？一种用于新型自身炎症性疾病的古老抗炎药物。
Rheumatology (Oxford). 2020 Jul 1;59(7):1769-1770. doi: 10.1093/rheumatology/keaa217.
6
Colchicine for the Treatment of Myocardial Injury in Patients With Coronavirus Disease 2019 (COVID-19)-An Old Drug With New Life?秋水仙碱用于治疗2019冠状病毒病（COVID-19）患者的心肌损伤——一种重获新生的老药？
JAMA Netw Open. 2020 Jun 1;3(6):e2013556. doi: 10.1001/jamanetworkopen.2020.13556.
7
Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19?秋水仙碱作为一种古老的抗炎药物，对新冠病毒肺炎是否有效？
J Clin Pharmacol. 2020 Jul;60(7):828-829. doi: 10.1002/jcph.1645. Epub 2020 May 23.
8
Colchicine may not be effective in COVID-19 infection; it may even be harmful?秋水仙碱可能对新型冠状病毒肺炎感染无效；甚至可能有害？
Clin Rheumatol. 2020 Jul;39(7):2101-2102. doi: 10.1007/s10067-020-05144-x. Epub 2020 May 11.
9
Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?秋水仙碱作为COVID-19的一种强效抗炎治疗方法：我们能让老狗学新把戏吗？
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):255. doi: 10.1093/ehjcvp/pvaa033.
10
Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS).氨苯砜、秋水仙碱和奥氮平作为辅助治疗药物预防新型冠状病毒肺炎相关的成人呼吸窘迫综合征（ARDS）。
Med Hypotheses. 2020 Aug;141:109774. doi: 10.1016/j.mehy.2020.109774. Epub 2020 Apr 23.
引用本文的文献
1
COVID-19 management in patients with comorbid conditions.合并症患者的 COVID-19 管理。
World J Virol. 2025 Jun 25;14(2):102674. doi: 10.5501/wjv.v14.i2.102674.
2
Host genetics and gut microbiota composition: Baseline gut microbiota composition as a possible prognostic factor for the severity of COVID-19 in patients with familial Mediterranean fever disease.宿主遗传学与肠道微生物群组成：作为家族性地中海热疾病患者 COVID-19 严重程度潜在预后因素的基线肠道微生物群组成
Front Microbiol. 2023 Mar 30;14:1107485. doi: 10.3389/fmicb.2023.1107485. eCollection 2023.
3
Common NLRP3 inflammasome inhibitors and Covid-19: Divide and conquer.常见的NLRP3炎性小体抑制剂与新冠病毒病：各个击破。
Sci Afr. 2022 Nov;18:e01407. doi: 10.1016/j.sciaf.2022.e01407. Epub 2022 Oct 22.
4
Current advancements and future prospects of COVID-19 vaccines and therapeutics: a narrative review.2019冠状病毒病疫苗与治疗方法的当前进展及未来前景：一篇叙述性综述
Ther Adv Vaccines Immunother. 2022 May 30;10:25151355221097559. doi: 10.1177/25151355221097559. eCollection 2022.
5
Efficacy of Colchicine in the Treatment of COVID-19 Patients: A Systematic Review and Meta-Analysis.秋水仙碱治疗新冠病毒肺炎患者的疗效：一项系统评价与荟萃分析
J Clin Med. 2022 May 6;11(9):2615. doi: 10.3390/jcm11092615.
6
Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trials.秋水仙碱治疗 COVID-19 患者的安全性和有效性：随机对照试验的系统评价和荟萃分析。
PLoS One. 2022 Apr 5;17(4):e0266245. doi: 10.1371/journal.pone.0266245. eCollection 2022.
7
-Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic.第二卷：SARS-CoV-2 大流行两年后感染或 mRNA 疫苗接种、药物治疗和非药物管理后的免疫。
Medicina (Kaunas). 2022 Feb 17;58(2):309. doi: 10.3390/medicina58020309.
8
Colchicine treatment in COVID-19: the remaining unsolved question.新冠肺炎中的秋水仙碱治疗：仍未解决的问题。
Lancet Respir Med. 2021 Dec;9(12):1351-1353. doi: 10.1016/S2213-2600(21)00462-8. Epub 2021 Oct 21.
9
Therapeutic potential of chelerythrine as a multi-purpose adjuvant for the treatment of COVID-19.白屈菜红碱作为一种多用途佐剂治疗 COVID-19 的治疗潜力。
Cell Cycle. 2021 Nov;20(22):2321-2336. doi: 10.1080/15384101.2021.1982509. Epub 2021 Sep 29.
10
SARS-CoV-2, Zika viruses and mycoplasma: Structure, pathogenesis and some treatment options in these emerging viral and bacterial infectious diseases.严重急性呼吸综合征冠状病毒 2 型、寨卡病毒和支原体：这些新发病毒性和细菌性传染病的结构、发病机制及一些治疗选择。
Biochim Biophys Acta Mol Basis Dis. 2021 Dec 1;1867(12):166264. doi: 10.1016/j.bbadis.2021.166264. Epub 2021 Sep 3.
本文引用的文献
1
Colchicine: A potential therapeutic tool against COVID-19. Experience of 5 patients.秋水仙碱：一种对抗新冠病毒的潜在治疗工具。5例患者的经验。
Reumatol Clin. 2021 Aug-Sep;17(7):371-375. doi: 10.1016/j.reuma.2020.05.001. Epub 2020 May 16.
2
Colchicine may not be effective in COVID-19 infection; it may even be harmful?秋水仙碱可能对新型冠状病毒肺炎感染无效；甚至可能有害？
Clin Rheumatol. 2020 Jul;39(7):2101-2102. doi: 10.1007/s10067-020-05144-x. Epub 2020 May 11.
3
Cardiac Tamponade Secondary to COVID-19.新型冠状病毒肺炎继发的心包填塞
JACC Case Rep. 2020 Jul 15;2(9):1326-1330. doi: 10.1016/j.jaccas.2020.04.009. Epub 2020 Apr 23.
4
Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.新型冠状病毒（COVI-19 或 SARS-CoV-2）诱导促炎细胞因子（IL-1 和 IL-6）和肺部炎症：抗炎策略。
J Biol Regul Homeost Agents. 2020;34(2):327-331. doi: 10.23812/CONTI-E.
5
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.中国武汉 2019 年冠状病毒病（COVID-19）患者免疫反应失调。
Clin Infect Dis. 2020 Jul 28;71(15):762-768. doi: 10.1093/cid/ciaa248.
6
Inhibition of respiratory syncytial virus replication and suppression of RSV-induced airway inflammation in neonatal rats by colchicine.秋水仙碱对新生大鼠呼吸道合胞病毒复制的抑制作用及对呼吸道合胞病毒诱导的气道炎症的抑制作用
3 Biotech. 2019 Nov;9(11):392. doi: 10.1007/s13205-019-1917-z. Epub 2019 Oct 10.
7
The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation.NLRP3 炎性小体与秋水仙碱抑制动脉粥样硬化相关炎症的新作用。
Atherosclerosis. 2018 Feb;269:262-271. doi: 10.1016/j.atherosclerosis.2017.12.027. Epub 2017 Dec 25.
8
Epstein-Barr Virus-related Acute Genital Ulcer Successfully Treated with Colchicine.秋水仙碱成功治疗与爱泼斯坦-巴尔病毒相关的急性生殖器溃疡
Acta Derm Venereol. 2018 Jan 12;98(1):134-135. doi: 10.2340/00015555-2761.
9
Colchicine poisoning: the dark side of an ancient drug.秋水仙碱中毒：一种古老药物的黑暗面。
Clin Toxicol (Phila). 2010 Jun;48(5):407-14. doi: 10.3109/15563650.2010.495348.
10
Colchicine: its mechanism of action and efficacy in crystal-induced inflammation.秋水仙碱：其在晶体诱导性炎症中的作用机制与疗效
Curr Rheumatol Rep. 2008 Jul;10(3):218-27. doi: 10.1007/s11926-008-0036-3.
Zotero 插件